Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.25603
Abstract: Background and objectives: Hypertherm intraperitoneal chemotherapy (HIPEC) is increasingly used in the treatment of ovarian, tubal, and primary peritoneal cancer (OC). The aim was to evaluate short‐term morbidity of cytoreductive surgery (CRS) and carboplatin HIPEC. read more here.
Keywords: peritoneal cancer; intraperitoneal chemotherapy; primary peritoneal; morbidity cytoreductive ... See more keywords
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.07.135
Abstract: OBJECTIVE To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. PATIENTS AND METHODS… read more here.
Keywords: peritoneal cancer; tubal peritoneal; weekly paclitaxel; ovarian tubal ... See more keywords
Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Obstetrics and Gynaecology"
DOI: 10.1080/01443615.2019.1634028
Abstract: Abstract The aim of this study was to evaluate overall survival (OS) and disease-free survival (DFS) of patients with Stage 3C serous ovarian, tubal and peritoneal carcinomas. A retrospective analysis of 111 patients who underwent… read more here.
Keywords: tubal peritoneal; optimal cytoreductive; cancer; ovarian tubal ... See more keywords